Neuropathic Pain Therapeutics
1. Cymbalta patent expiration
Treatment: Management of fibromyalgia (fm); Method of treating anxiety
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(5 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(11 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(6 years ago) | |
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(12 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(12 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-617) | Nov 19, 2012 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | Apr 18, 2016 |
| M(M-61) | Oct 18, 2015 |
| New Patient Population(NPP) | Apr 20, 2023 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Dosage: CAPSULE, DELAYED REL PELLETS
How can I launch a generic of CYMBALTA before it's drug patent expiration?
More Information on Dosage
CYMBALTA family patents
2. Horizant patent expiration
Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults
HORIZANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(9 months ago) | |
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(3 years ago) | |
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(3 months from now) | |
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(11 months ago) | |
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
3. Lyrica patent
expiration
Treatment: Management of fibromyalgia; Treatment of seizure disorder; Treatment of pain, including neuropathic pain associated with diabetic peripheral...
LYRICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(7 years ago) | |
| US6001876 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
|
US6001876 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| US5563175 | UPJOHN | GABA and L-glutamic acid analogs for antiseizure treatment |
Oct, 2013
(12 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(6 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-651) | Jun 20, 2015 |
| M(M-193) | Dec 22, 2019 |
| New Patient Population(NPP) | May 23, 2022 |
| Pediatric Exclusivity(PED) | Nov 23, 2022 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 30 December, 2004
Dosage: CAPSULE; SOLUTION
How can I launch a generic of LYRICA before it's drug patent expiration?
More Information on Dosage
LYRICA family patents
4. Qutenza patent expiration
Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263059 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US10869827 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US6239180 | AVERITAS | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
Nov, 2016
(9 years ago) | |
| US8889113 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US10463598 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US9226903 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
Dec, 2028
(2 years from now) | |
| US10034841 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
Sep, 2025
(4 months ago) | |
| US8821920 | AVERITAS | Therapeutic patch for transdermal delivery of capsaicin |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
| New Indication(I-838) | Jul 17, 2023 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Dosage: PATCH
More Information on Dosage
QUTENZA family patents